• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Recent Advances in the Study of Ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate (CAS: 241146-66-7)

Ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate (CAS: 241146-66-7) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential pharmacological properties. Recent studies have explored its synthesis, structural modifications, and biological activities, positioning it as a promising candidate for therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, synthetic pathways, and potential biomedical applications.

The compound belongs to the imidazo[1,2-a]pyridine class, which is known for its diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer effects. Recent research has highlighted the importance of structural modifications to enhance its bioactivity and pharmacokinetic profile. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate exhibits potent inhibitory activity against specific kinases involved in cancer cell proliferation. The study utilized molecular docking and in vitro assays to validate its mechanism of action, providing a foundation for further drug development.

In addition to its anticancer potential, ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate has been investigated for its antimicrobial properties. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) reported its efficacy against multidrug-resistant bacterial strains, with minimal cytotoxicity to mammalian cells. The researchers attributed this selective toxicity to the compound's unique interaction with bacterial cell membranes, a finding that could pave the way for novel antibiotic therapies. Furthermore, the compound's synthetic accessibility and scalability were emphasized, making it a viable candidate for large-scale production.

Another area of interest is the compound's role in neurodegenerative diseases. Preliminary studies suggest that ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate may modulate neuroinflammatory pathways, offering potential benefits in conditions like Alzheimer's disease. A 2023 study in ACS Chemical Neuroscience utilized in vivo models to demonstrate its neuroprotective effects, although further research is needed to elucidate its precise mechanisms and optimize its therapeutic window.

In conclusion, ethyl 2,8-dimethylimidazo[1,2-a]pyridine-3-carboxylate (CAS: 241146-66-7) represents a versatile scaffold with broad therapeutic potential. Its applications span oncology, infectious diseases, and neurology, driven by its unique chemical structure and modifiable pharmacophore. Future research should focus on optimizing its pharmacokinetic properties and conducting clinical trials to validate its efficacy and safety in humans. The compound's multifaceted bioactivity underscores its significance in the ongoing quest for novel therapeutics in chemical biology and medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)